Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
High-Dose vs Standard-Dose Cytarabine and IL-2 in AML (AML-12)
NCT00004128Phase 3Unknown
- Sponsor
- European Organisation for Research and Treatment of Cancer
- Start
- Sep 1999
- Primary completion
- Jan 2008
- Modality
- Cytokines & Interferons, Small Molecules
01
Overview
A Phase 3 trial of cytarabine, aldesleukin in acute myeloid leukemia (AML), sponsored by European Organisation for Research and Treatment of Cancer. Status: unknown.
02
Drugs
cytarabinealdesleukin
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT00004128.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00004128.